Roche vet Sandra Horning jumps on biopharma board no. 3 — what’s that worth?

John Carroll

Editor & Founder

Sandra Horning is in high demand.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Roche vet Sandra Horning jumps on biopharma board no. 3 — what’s that worth?

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

Amgen touts new data for obesity drug MariTide, moving rapidly into Phase 3 work

Lonnel Coats announces retirement from Lexicon; Another shakeup in Vir's C-suite

FTC wants more information on Novo-Catalent deal in antitrust review

CG Oncology touts interim Phase 3 bladder cancer data, gears up to compete with ImmunityBio

Royalty Pharma's milestone payment to Arrowhead; Abeona's $75M offering

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Roche vet San­dra Horn­ing jumps on bio­phar­ma board no. 3 — what’s that worth?

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Benchling

San Francisco, CA, USA

Roche vet Sandra Horning jumps on biopharma board no. 3 — what’s that worth?